Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NTHI
Strong SellSinkerNeOnc Technologies Holdings, Inc. · Healthcare · United States · $122M · Avg Vol: $900K/d
COMPANY DESCRIPTION
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for difficult-to-treat cancers, particularly brain tumors, using proprietary nanotechnology and drug delivery systems. The company's unique approach aims to overcome the blood-brain barrier, allowing for targeted drug delivery to enhance efficacy and reduce systemic toxicity. NeOnc seeks to address significant unmet medical needs in oncology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 20.0K | 70.5K | 83.0K | 40.0K | 26.0% | 40.0K | — | — | — |
| EPS | -0.18 | -0.16 | -0.80 | -0.63 | -3.20 | — | -2.12 | -1.35 | -1.01 | — |
| Shares | 18.7M | 18.7M | 18.7M | 18.7M | 21.7M | +15.7% | 25.9M | — | — | — |
| Debt | 1.1M | 50.0K | 6.6M | 24.7K | 6.3M | 53.1% | 0.3M | — | — | — |
| Equity | -2.6M | -1.6M | -14.0M | -5.5M | -17.5M | — | — | — | — | — |
| Op CF | -0.4M | -0.9M | -1.9M | -4.2M | -20.4M | — | -21.2M | — | — | — |
| Inv CF | — | — | — | 0 | -0.5M | — | — | — | — | — |
| Fin CF | 0.3M | 1.5M | 1.3M | 4.2M | 20.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NTHI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NTHI | NeOnc Technologies Holdings, Inc.(you) | $122M | 0 | Strong Sell |
| CBUS | Cibus, Inc. | $126M | 2 | Strong Sell |
| 2592.HK | Cloudbreak Pharma Inc. | $136M | 1 | Strong Sell |
| INO | Inovio Pharmaceuticals, Inc. | $133M | 3 | Strong Sell |
| GNLX | Genelux Corporation | $120M | 4 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%